Stock Events

Stock Events

Nykode Therapeutics AS 

$0.3542
69
-$0.00-0% Tuesday 20:00

Statistics

Day High
0.3631
Day Low
0.3631
52W High
0.38
52W Low
0.15575
Volume
1,000
Avg. Volume
47
Mkt Cap
115.66M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Dividends

0%Dividend Yield
Jun 25
$0.10
Jun 25
$0.10
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

25NovExpected
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Q1 2026
Next
Next
-0.21
-0.2
-0.2
-0.19
Expected EPS
N/A
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-12.24MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow VACBF. It's not an investment recommendation.
Var Energi ASA
16
VAR.OL
MPC Container Ships ASA
13
MPCC.OL
Yara International ASA.
13
YAR.OL
Hoegh Autoliners ASA
9
HAUTO.OL

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Moderna
MRNA
Mkt Cap55.09B
Moderna is a leader in mRNA technology, directly competing in the vaccine and therapeutic space similar to Nykode's focus on novel immunotherapies.
BioNTech
BNTX
Mkt Cap25.64B
BioNTech competes in the development of novel mRNA vaccines and therapeutics, similar to Nykode's approach in immunotherapy.
Novavax
NVAX
Mkt Cap1.53B
Novavax is involved in the development of vaccines for infectious diseases, competing with Nykode's vaccine development efforts.
Pfizer
PFE
Mkt Cap159.36B
Pfizer develops and markets vaccines and therapeutics, including mRNA vaccines, competing in the same space as Nykode.
GSK
GSK
Mkt Cap101.78B
GlaxoSmithKline focuses on vaccines and therapeutics, including efforts in the immunotherapy space, making it a competitor.
Johnson & Johnson
JNJ
Mkt Cap645.95B
Johnson & Johnson develops vaccines and therapeutics, including efforts in immunotherapy, competing with Nykode's product pipeline.
Astrazeneca
AZN
Mkt Cap252.33B
AstraZeneca is involved in the development of vaccines and therapeutics, including immunotherapy treatments, competing with Nykode.
Arcturus Therapeutics
ARCT
Mkt Cap431.75M
Arcturus Therapeutics is engaged in mRNA vaccine and therapeutic development, competing in the same technological space as Nykode.
Incyte
INCY
Mkt Cap25.21B
Incyte focuses on the discovery, development, and commercialization of therapeutics, including immunotherapies, making it a competitor in the same field as Nykode.

About

Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies for the treatment of cancer and autoimmune diseases. The company develops vaccines for the treatment cancer, autoimmune, and infectious diseases. Its lead product candidates include ABI-SUVA for targeting HPV16+ induced malignancies, with head, and neck cancer as the primary indication is in Phase 2 randomized controlled trial. It also offers VB10.NEO, which is in Phase1b VB-N-02 trial; technology platform, which combines genes with desired properties to make novel compounds by creating a new code. Nykode Therapeutics AS was founded in 2006 and is headquartered in Oslo, Norway.
Show more...
CEO
Mr. Michael Thyring Engsig
Country
Other
ISIN
NO0010714785
WKN
000A2PZ5J

Listings

F
DE
5VB.F
STU
DE
5VB.STU
MU
DE
5VB.MU
OTC Link
US
VACBF

0 Comments

Share your thoughts

FAQ

What is Nykode Therapeutics AS stock price today?▼
The current price of VACBF is $0.35 USD — it has decreased by -0% in the past 24 hours. Watch Nykode Therapeutics AS stock price performance more closely on the chart.
What is Nykode Therapeutics AS stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on OTC Link exchange Nykode Therapeutics AS stocks are traded under the ticker VACBF.
Is Nykode Therapeutics AS stock price growing?▼
VACBF stock has risen by +0% compared to the previous week, the month change is a +10.24% rise, over the last year Nykode Therapeutics AS has showed a +69.47% increase.
What is Nykode Therapeutics AS market cap?▼
Today Nykode Therapeutics AS has the market capitalization of 115.66M
When is the next Nykode Therapeutics AS earnings date?▼
Nykode Therapeutics AS is going to release the next earnings report on November 25, 2026.
What is Nykode Therapeutics AS revenue for the last year?▼
Nykode Therapeutics AS revenue for the last year amounts to 0 USD.
What is Nykode Therapeutics AS net income for the last year?▼
VACBF net income for the last year is -12.24M USD.
Does Nykode Therapeutics AS pay dividends?▼
Yes, VACBF dividends are paid annual. The last dividend per share was 0.1 USD. As of today, Dividend Yield (FWD)% is 0%.
In which sector is Nykode Therapeutics AS located?▼
Nykode Therapeutics AS operates in the Health & Wellness sector.
When did Nykode Therapeutics AS complete a stock split?▼
The last stock split for Nykode Therapeutics AS was on July 07, 2020 with a ratio of 5:1.
Where is Nykode Therapeutics AS headquartered?▼
Nykode Therapeutics AS is headquartered in Oslo, Other.